Oslo Cancer Cluster - Norwegian Centres of Expertise

Members

The members of Oslo Cancer Cluster

We are a non-profit member organization comprising over 60 members commited to improving the lives of cancer patients.

Our members include academic research institutions, biotech companies, pharmaceutical companies, industry, health initiatives, support groups, financial institutions and regional development players in the field of cancer R&D.

We are actively recruiting members and are open for international members as well. Today we have members from all over Scandinavia as well as Scotland.

DiaGenic ASA
Grenseveien 92
0663 Oslo

CEO: Erik Christensen
PHONE: +4723248950
E-MAIL: erik.christensen@diagenic.com
WEB: www.diagenic.com

FOUNDED IN: 1998
NUMBER OF EMPLOYEES: 23
PRODUCT PIPELINE: Blood based diagnostic test for early detection of breast cancer, Alzheiemrs and Parkinsons disease
PRODUCTS ON MARKET: BCtect - blood based breast cancer test
ADtect - blood based Alzheimer's Disease test

CORE EXPERTISE:
Gene expression in blood, RNA, PCR
Bioinformatics
Diagnostic test development
Clinical studies

COMPANY DESCRIPTION:
DiaGenic ASA is an innovative Norwegian in vitro diagnostic company founded in 1998 and listed on the Oslo Stock Exchange.

DiaGenic develops patient-friendly diagnostic tests for the early detection of devastating diseases where early intervention is crucial for successful treatment. DiaGenic’s patented method is based on identifying disease-specific gene expression signatures from easily available sample material such as blood.

DiaGenic's first two products, ADtect® for early detection of Alzheimer’s disease and BCtect® for early detection of breast cancer, have received regulatory approval for Europe, CE mark, and are now being launched in selected markets in Europe.

DiaGenic has an existing pipeline of projects focusing on discovery and documentation of gene expression signatures for Parkinson's Disease and for identification of patients with Mild Cognitive Impairment that will convert to Alzheimer’s disease.

The company is a leader in discovery and development of diagnostic tests based on peripheral gene expression profiling.

The diagnostic tests together with an R&D cooperation with a major pharmaceutical company forms the basis of the company’s biomarker strategy enabling early disease detection for clinical trials.

VALUE CHAIN

BUSINESS MODEL

SECTOR